Replies to post #147852 on Biotech Values

[iwfal]

The issue is not that warfarin patients in Europe have been shifted en masse to the new oral anticoagulants, but rather that warfarin was not heavily used in Europe in the first place, despite its being the quasi-official SoC for certain indications.

Thanks, and agree that it is probable that Coumadin, per se, is not as highly prescribed in Europe. Because alternative vitamin k antagonists are prescribed instead (e.g. Acenocoumarol or Phenprocoumon). But would suggest that the correct metric is new anti-coags vs vitamin k antagonists as a class.